93B9C99A-08DD-4F78-9CF5-C59A01605C9D
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 9.165571616294349
- age_years
- 38
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.496
- MYC_TARGETS_V1+0.466
- OXIDATIVE_PHOSPHORYLATION+0.442
- PROTEIN_SECRETION+0.336
- UNFOLDED_PROTEIN_RESPONSE+0.327
- DNA_REPAIR+0.297
- CHOLESTEROL_HOMEOSTASIS+0.292
- HEDGEHOG_SIGNALING+0.284
- MTORC1_SIGNALING+0.277
- E2F_TARGETS+0.276
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.429
- COAGULATION-0.425
- IL6_JAK_STAT3_SIGNALING-0.395
- ALLOGRAFT_REJECTION-0.381
- MYOGENESIS-0.380
- INFLAMMATORY_RESPONSE-0.342
- IL2_STAT5_SIGNALING-0.316
- TNFA_SIGNALING_VIA_NFKB-0.297
- KRAS_SIGNALING_DN-0.287
- ANGIOGENESIS-0.271
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2C70D7BF-85C4-447B-B0F9-A129D6B49E77 | — | — | 0.947 |
| 2 | 713B4DA5-FA8A-4E52-BACF-19B912467FBB | — | — | 0.921 |
| 3 | E3A67B7B-7427-4C11-912B-166451072767 | — | — | 0.919 |
| 4 | 332283CB-F855-4493-A259-7852FD37B9DC | — | — | 0.918 |
| 5 | B9E0623C-E3AC-4B2B-983E-C2246AD0DB00 | — | — | 0.918 |
| 6 | 10FB7E59-9D71-4AB9-8D06-9CFD2304D1BC | — | — | 0.915 |
| 7 | 1C94EA93-563D-4F65-B857-85EF91127874 | — | — | 0.911 |
| 8 | E79FE058-F03E-45F3-A939-356B0427E1B7 | — | — | 0.905 |
| 9 | A5D67B9F-5558-48FC-81A3-642D1903DA1F | — | — | 0.904 |
| 10 | SRR934718 | — | — | 0.902 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.496 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.466 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.442 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.336 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.327 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.297 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.292 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.284 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.277 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.276 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.267 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.241 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.216 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.203 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.198 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| NOTCH_SIGNALING | 0.127 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.094 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.066 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.047 | Idelalisib | — uncovered |